Cibc World Market Inc. Has $26.47 Million Stake in Zoetis Inc. (NYSE:ZTS)

Cibc World Market Inc. raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 44.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 162,446 shares of the company's stock after purchasing an additional 49,774 shares during the quarter. Cibc World Market Inc.'s holdings in Zoetis were worth $26,467,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ZTS. State Street Corp raised its position in Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company's stock worth $3,864,488,000 after acquiring an additional 95,856 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock valued at $2,030,813,000 after acquiring an additional 185,364 shares during the period. Mizuho Securities USA LLC boosted its stake in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after purchasing an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock worth $761,221,000 after purchasing an additional 194,542 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock valued at $569,834,000 after purchasing an additional 279,092 shares during the period. Institutional investors own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ZTS. Morgan Stanley lowered their price target on Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price target on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $215.00.

Zoetis Stock Performance

NYSE ZTS traded up $0.13 during midday trading on Tuesday, hitting $172.07. The company had a trading volume of 1,437,550 shares, compared to its average volume of 2,625,104. The firm has a fifty day simple moving average of $169.48 and a two-hundred day simple moving average of $179.39. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market cap of $77.63 billion, a price-to-earnings ratio of 32.30, a P/E/G ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts' expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company's revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.36 EPS. Equities analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a boost from Zoetis's previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. Zoetis's dividend payout ratio is currently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.